ARTICLE
10 January 2025

Top Ten Rx IP Update Reads Of 2024

SB
Smart & Biggar

Contributor

Smart & Biggar uncovers and maximizes intellectual property and technology assets for our clients. Today’s fast-paced innovation economy demands a higher level of expertise and attention to detail when it comes to IP strategy and protection. With over 125 lawyers, patent agents and trademark agents collaborating across five Canadian offices, Smart & Biggar is trusted by the world’s leading innovators to find value in their IP rights. As market leaders in IP, Smart & Biggar’s team is on the pulse when it comes to the latest developments and the wider industry changes that impact our clients. To stay informed, visit smartbiggar.ca/insights, including access to our RxIP Update (smartbiggar.ca/insights/rx-ip-updates), a monthly digest of the latest decisions and law surrounding the life sciences and pharmaceutical industries.
Below are Rx IP Update's most-read articles of 2024 (see also our 2024 highlights in Canadian life sciences IP and regulatory law)...
Canada Intellectual Property

Below are Rx IP Update's most-read articles of 2024 (see also our 2024 highlights in Canadian life sciences IP and regulatory law):

  1. Update on biosimilars in Canada – March 2024
  2. Federal Court finds PMPRB reasonably concluded Galderma's patent claiming 0.3% adapalene "pertained to" 0.1% adapalene DIFFERIN
  3. Federal Court of Appeal affirms paliperidone palmitate claims are not unpatentable methods of medical treatment
  4. Evolving pharmacy landscape signals more stringent regulatory scrutiny of "patient steering"
  5. LUMIGAN RC formulation patent found valid and infringed
  6. Twice is not nice – second notice of allegation may be abusive
  7. Boehringer Ingelheim succeeds in nintedanib PMNOC action against JAMP
  8. U.S. FDA authorizes Florida plan to import drugs in bulk from Canada
  9. Discussion Guide for PMPRB Phase 2 Consultations on New Guidelines outlines proposed new framework for patented medicine price review [see also latest update: PMPRB releases new Draft Guidelines for comment]
  10. PM(NOC) Regulations: seven-year anniversary of major amendments

The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More